Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sergio Sequera-Arquelladas"'
Autor:
Sergio Sequera-Arquelladas, Carmen Hidalgo-Tenorio, Luis López-Cortés, Alicia Gutiérrez, Jesús Santos, Francisco Téllez, Mohamed Omar, Sergio Ferra-Murcia, Elisa Fernández, Rosario Javier, Coral García-Vallecillos, Juan Pasquau
Publikováno v:
Viruses, Vol 16, Iss 2, p 259 (2024)
The continuous pharmacological advances in antiretroviral treatment (ART) and the increasing understanding of HIV drug resistance has led to a change in the paradigm of ART optimization in the setting of the viral suppression of treatment-experienced
Externí odkaz:
https://doaj.org/article/2e2eeeff682a4538bc7096d75b4e4eae
Autor:
Noelia Lozano, Mercedes Gomez Samblas, Eva Calabuig, María José Giménez Martí, Maria Dolores Gómez Ruiz, José Miguel Sahuquillo Arce, Sergio Sequera-Arquelladas, José Miguel Molina Moreno, M Trelis, Antonio Osuna
Publikováno v:
PLoS ONE, Vol 18, Iss 9, p e0282814 (2023)
Chagas disease, a neglected tropical disease, is now considered a worldwide health concern as a result of migratory movements from Central and South America to other regions that were considered free of the disease, and where the epidemiological risk
Externí odkaz:
https://doaj.org/article/a8688e800c90498ba39dc1cd911f8237
Autor:
Covid Virgen de las Nieves Team, Carmen Hidalgo-Tenorio, Coral García-Vallecillos, Sergio Sequera-Arquelladas
Publikováno v:
Medicine
Remdesivir is the only antiviral approved for lower respiratory tract infection produced by SARS-CoV-2. The main objective of this study was to determine the mortality rate, readmissions, mean hospital stay, need for higher levels of oxygen support,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c92d91a90d3c7b6b9e631f5d2705f215
https://pubmed.ncbi.nlm.nih.gov/34664862
https://pubmed.ncbi.nlm.nih.gov/34664862
Autor:
Miguel Salavert Lletí, Mireia Mensa Vendrell, Laura Ruiz, Ester López Suñé, Josep Mensa Pueyo, Sergio Sequera Arquelladas, Maria Rosa Oltra Sempere, José Ramón Yuste Ara, Juan Pasquau Liaño, Valentina Isernia, Leonor Moreno Nuñez, Eva Calabuig Muñoz, Alex Soriano Viladomiu, María Tasias Pitarch, Maria-Luisa Pedro-Botet Montoya, Genís Castells Lao, Esteban Alberto Reynaga Sosa
Publikováno v:
Antimicrob Agents Chemother
Tedizolid has demonstrated its efficacy and safety in clinical trials; however, data concerning its tolerability in long-term treatments are scarce. The aim of the study was to assess the indications and to describe the long-term safety profile of te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa8e00dc35c52cdfb6d83085eac39119
https://hdl.handle.net/10668/15398
https://hdl.handle.net/10668/15398
